Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study (updated)

Aldeyra Therapeutics

19/12/2023 12:27

(Adds details throughout)
       Dec 19 (Reuters) - Aldeyra Therapeutics  ALDX.O  said on
Tuesday its experimental drug to treat a type of chronic skin
disease was safe and well tolerated in a mid-stage study.
        The drug, ADX-629, also helped reduce the severity of
eczema symptoms in adult patients with mild to moderate atopic
dermatitis, the Lexington, Massachusetts-based company said.
  
       ADX-629 belongs to a class of medicines called RASP
modulators designed to reduce levels of specific
inflammation-causing chemical compounds.
  
       Atopic dermatitis is characterized by itchy, dry, and
inflamed skin and affects about 16.5 million adults and more
than 9.6 million children in the United States, according to
Aldeyra. 
  

 (Reporting by Mariam Sunny and Puyaan Singh in Bengaluru;
Editing by Anil D'Silva and Tasim Zahid)
 ((Mariam.ESunny@thomsonreuters.com;))